Market revenue in 2023 | USD 85.4 million |
Market revenue in 2030 | USD 218.5 million |
Growth rate | 14.4% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Sequencing & Data Analytics Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Kits & Reagents, Sequencing & Data Analytics Services, Software |
Key market players worldwide | Bio-Rad Laboratories Inc, Illumina Inc, PerkinElmer, Thermo Fisher Scientific Inc, Novogene, Promega, Qiagen NV, Takara Bio Inc, Oxford Nanopore Technologies PLC, Roche Holding AG |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to metagenomics market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 61.48% in 2023. Horizon Databook has segmented the Japan metagenomics market based on kits & reagents, sequencing & data analytics services, software covering the revenue growth of each sub-segment from 2018 to 2030.
Healthcare and clinical research service providers in Japan have been integrating Next-Generation Sequencing (NGS) technologies for the past couple of years. They are expected to account for a considerable share of Asia Pacific metagenomics revenue share. Ongoing developments in HLA and prenatal NGS testing, coupled with international collaborations with U.S. & European companies, are expected to fuel the growth of Japan metagenomics market during the forecast period.
Moreover, many hospitals in Japan have started using NGS-based mutational profile screening for patients with solid tumors to direct patients to relevant clinical trials. Various cancer gene panels to be used in clinical practice have also been approved by the Ministry of Health, Labour and Welfare of Japan.
However, a medical protocol for reporting and interpreting clinical variants must be developed. Using sequencing technology in this field, significant progress has been made in understanding the molecular causes of cancer. These factors are driving the market growth in the country. Since 2013, various Japanese institutions and university hospitals have commenced research based on NGS clinical sequencing to meet the rising demand for cancer & targeted therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan metagenomics market , including forecasts for subscribers. This country databook contains high-level insights into Japan metagenomics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account